CoChat

Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy

Malerba, Alberto, Roth, Fanny, Harish, Pradeep, Dhiab, Jamila, Lu-Nguyen, Ngoc, Cappellari, Ornella, Jarmin, Susan, Mahoudeau, Alexandrine, Ythier, Victor, Lainé, Jeanne, Negroni, Elisa, Abgueguen, Emmanuelle, Simonelig, Martine, Guedat, Philippe, Mouly, Vincent, Butler-Browne, Gillian, Voisset, Cécile, Dickson, George, Trollet, Capucine · 2019 · Human Molecular Genetics
Cited by 33

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddz007

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 71

  1. Abu-Baker, 2007, Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies, Biochim. Biophys. Acta, 1772, 173, 10.1016/j.bbadis.2006.10.003 · DOI
  2. Brais, 1998, Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy, Nat. Genet., 18, 164, 10.1038/ng0298-164 · DOI · Paper page
  3. Apponi, 2010, Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis, Hum. Mol. Genet., 19, 1058, 10.1093/hmg/ddp569 · DOI · Paper page
  4. Benoit, 2005, An essential cytoplasmic function for the nuclear poly(A) binding protein, PABP2, in poly(A) tail length control and early development in Drosophila, Dev. Cell, 9, 511, 10.1016/j.devcel.2005.09.002 · DOI
  5. Jenal, 2012, The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites, Cell, 149, 538, 10.1016/j.cell.2012.03.022 · DOI · Paper page
  6. Klerk, 2012, Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation, Nucleic Acids Res., 40, 9089, 10.1093/nar/gks655 · DOI · Paper page
  7. Bergeron, 2015, Regulated intron retention and nuclear pre-mRNA decay contribute to PABPN1 autoregulation, Mol. Cell. Biol., 35, 2503, 10.1128/MCB.00070-15 · DOI
  8. Muniz, 2015, Poly(A) polymerase and the nuclear poly(A) binding protein, PABPN1, coordinate the splicing and degradation of a subset of human pre-mRNAs, Mol. Cell. Biol., 35, 2218, 10.1128/MCB.00123-15 · DOI
  9. Beaulieu, 2012, Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)- binding protein nuclear 1, PLoS Genet., 8, 10.1371/journal.pgen.1003078 · DOI · Paper page
  10. Bresson, 2013, The human nuclear poly(A)- binding protein promotes RNA hyperadenylation and decay, PLoS Genet., 9, 10.1371/journal.pgen.1003893 · DOI · Paper page
  11. Banerjee, 2017, Nuclear poly(A) binding protein 1 (PABPN1) and Matrin3 interact in muscle cells and regulate RNA processing, Nucleic Acids Res., 45, 10706, 10.1093/nar/gkx786 · DOI · Paper page
  12. Apponi, 2013, Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle, Skelet. Muscle, 3, 23, 10.1186/2044-5040-3-23 · DOI · Paper page
  13. Gidaro, 2013, Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients, J. Neuropathol. Exp. Neurol., 72, 234, 10.1097/NEN.0b013e3182854c07 · DOI
  14. Tomé, 1980, Nuclear inclusions in oculopharyngeal dystrophy, Acta Neuropathol. (Berl.), 49, 85, 10.1007/BF00692226 · DOI
  15. Anvar, 2013, A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging, Aging, 5, 412, 10.18632/aging.100567 · DOI
  16. Malerba, 2017, PABPN1 gene therapy for oculopharyngeal muscular dystrophy, Nat. Commun., 8, 14848, 10.1038/ncomms14848 · DOI · Paper page
  17. Vest, 2017, Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology, Hum. Mol. Genet., 26, 3235, 10.1093/hmg/ddx206 · DOI · Paper page
  18. Blumen, 1999, Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease, Ann. Neurol., 46, 115, 10.1002/1531-8249(199907)46:1<115::AID-ANA17>3.0.CO;2-O · doi:10.1002/1531-8249(199907)46:1<115::aid-ana17>3.0.co;2-o
  19. Abu-Baker, 2013, Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/β-catenin pathway, Cell Death Dis., 4, e821, 10.1038/cddis.2013.342 · DOI
  20. Bao, 2002, Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy, J. Biol. Chem., 277, 12263, 10.1074/jbc.M109633200 · DOI · Paper page
  21. Bao, 2004, Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy, J. Med. Genet., 41, 47, 10.1136/jmg.2003.014548 · DOI
  22. Barbezier, 2011, Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy, EMBO Mol. Med., 3, 35, 10.1002/emmm.201000109 · DOI
  23. Davies, 2005, Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice, Nat. Med., 11, 672, 10.1038/nm1242 · DOI · Paper page
  24. Anvar, 2011, Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients, Skelet. Muscle, 1, 10.1186/2044-5040-1-15 · DOI
  25. Davies, 2010, Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy, Sci. Transl. Med., 2, 34ra40, 10.1126/scitranslmed.3000723 · DOI
  26. Périé, 2014, Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study, Mol. Ther., 22, 219, 10.1038/mt.2013.155 · DOI
  27. Argov, 2016, Intravenous trehalose improves dysphagia and muscle function in oculopharyngeal muscular dystrophy (OPMD): preliminary results of 24 weeks open label phase 2 trial (I4.007), Neurology, 86, I4.007, 10.1212/WNL.86.16_supplement.I4.007 · doi:10.1212/wnl.86.16_supplement.i4.007
  28. Nash, 1973, Clinical trial with guanabenz, a new antihypertensive agent, J. Clin. Pharmacol., 13, 416
  29. Tribouillard-Tanvier, 2008, Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions, PloS One, 3, e1981, 10.1371/journal.pone.0001981 · doi:10.1371/journal.pone.0001981
  30. Blondel, 2016, Protein folding activity of the ribosome is involved in yeast prion propagation, Sci. Rep., 6, 32117, 10.1038/srep32117 · DOI
  31. Nguyen, 2014, Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost α2-adrenergic receptor agonistic activity, ACS Chem. Neurosci., 5, 1075, 10.1021/cn5001588 · DOI
  32. Reis, 2011, Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding, Biochimie, 93, 1047, 10.1016/j.biochi.2011.03.002 · doi:10.1016/j.biochi.2011.03.002
  33. Vieira, 2015, Guanabenz treatment accelerates disease in a mutant SOD1 mouse model of ALS, PloS One, 10, e0135570, 10.1371/journal.pone.0135570 · DOI
  34. Wang, 2014, Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis, Neurobiol. Dis., 71, 317, 10.1016/j.nbd.2014.08.010 · DOI · Paper page
  35. Tsaytler, 2011, Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis, Science, 332, 91, 10.1126/science.1201396 · DOI · Paper page
  36. Carrara, 2017, Decoding the selectivity of eIF2α holophosphatases and PPP1R15A inhibitors, Nat. Struct. Mol. Biol., 24, 708, 10.1038/nsmb.3443 · DOI · Paper page
  37. Das, 2015, Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit, Science, 348, 239, 10.1126/science.aaa4484 · DOI · Paper page
  38. Choy, 2015, Structural and functional analysis of the GADD34:PP1 eIF2α phosphatase, Cell Rep., 11, 1885, 10.1016/j.celrep.2015.05.043 · DOI · Paper page
  39. Crespillo-Casado, 2017, PPP1R15A-mediated dephosphorylation of eIF2α is unaffected by Sephin1 or guanabenz, Elife, 6, 10.7554/eLife.26109 · DOI · Paper page
  40. Crespillo-Casado, 2018, A Sephin1-insensitive tripartite holophosphatase dephosphorylates translation initiation factor 2α, J. Biol. Chem., 293, 7766, 10.1074/jbc.RA118.002325 · DOI
  41. Klein, 2016, Nuclear poly(A)-binding protein aggregates misplace a pre-mRNA outside of SC35 speckle causing its abnormal splicing, Nucleic Acids Res., 10.1093/nar/gkw703 · DOI · Paper page
  42. Raz, 2011, Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein, Am. J. Pathol., 179, 1988, 10.1016/j.ajpath.2011.06.044 · DOI · Paper page
  43. Neuber, 2014, Guanabenz interferes with ER stress and exerts protective effects in cardiac myocytes, PLoS One, 9, e98893, 10.1371/journal.pone.0098893 · DOI
  44. Akiyama, 2009, Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice, Diabetologia, 52, 653, 10.1007/s00125-009-1270-6 · DOI
  45. Riggs, 2005, Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis, Diabetologia, 48, 2313, 10.1007/s00125-005-1947-4 · DOI · Paper page
  46. Weidler, 1984, Dose-response relationship of single oral doses of guanabenz in hypertensive patients, J. Cardiovasc. Pharmacol., 6, S762, 10.1097/00005344-198400065-00007 · doi:10.1097/00005344-198400065-00007
  47. Walker, 1981, Long-term therapy of hypertension with guanabenz, Clin. Ther., 4, 217
  48. Trollet, 2010, Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres, Hum. Mol. Genet., 19, 2191, 10.1093/hmg/ddq098 · DOI
  49. Lindholm, 2017, Recent insights into the role of unfolded protein response in ER stress in health and disease, Front. Cell Dev. Biol., 5, 48, 10.3389/fcell.2017.00048 · DOI · Paper page
  50. Reyes, 1981, Intracellular spiral inclusions in cerebral cell processes in Creutzfeldt–Jakob disease, J. Neuropathol. Exp. Neurol., 40, 1, 10.1097/00005072-198101000-00001 · doi:10.1097/00005072-198101000-00001
  51. Tanaka, 2000, Immunohistochemical studies of the PrP(CJD) deposition in Creutzfeldt–Jakob disease, Neuropathology, 20, 124, 10.1046/j.1440-1789.2000.00285.x · DOI
  52. Tsuru, 2016, Novel mechanism of enhancing IRE1α-XBP1 signalling via the PERK-ATF4 pathway, Sci. Rep., 6, 24217, 10.1038/srep24217 · DOI
  53. Byrd, 2012, MicroRNA-30c-2* limits expression of proadaptive factor XBP1 in the unfolded protein response, J. Cell Biol., 196, 689, 10.1083/jcb.201201077 · DOI · Paper page
  54. Chhabra, 2011, Gene expression profiling indicate role of ER stress in miR-23a~27a~24-2 cluster induced apoptosis in HEK293T cells, RNA Biol., 8, 648, 10.4161/rna.8.4.15583 · DOI · Paper page
  55. Chartier, 2006, A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1, EMBO J., 25, 2253, 10.1038/sj.emboj.7601117 · DOI · Paper page
  56. Chartier, 2015, Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis, PLoS Genet., 11, 10.1371/journal.pgen.1005092 · DOI
  57. Brown, 2012, The endoplasmic reticulum stress response in aging and age-related diseases, Front. Physiol., 3, 263, 10.3389/fphys.2012.00263 · DOI · Paper page
  58. Fritz, 2014, Deficiency of the BiP cochaperone ERdj4 causes constitutive endoplasmic reticulum stress and metabolic defects, Mol. Biol. Cell, 25, 431, 10.1091/mbc.e13-06-0319 · DOI
  59. Harding, 2003, An integrated stress response regulates amino acid metabolism and resistance to oxidative stress, Mol. Cell, 11, 619, 10.1016/S1097-2765(03)00105-9 · DOI · Paper page
  60. Jiang, 2014, Nutrient deprivation induces α-synuclein aggregation through endoplasmic reticulum stress response and SREBP2 pathway, Front. Aging Neurosci., 6, 268, 10.3389/fnagi.2014.00268 · DOI
  61. Krebs, 2015, Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: an integrated view of calcium signaling, Biochem. Biophys. Res. Commun., 460, 114, 10.1016/j.bbrc.2015.02.004 · DOI · Paper page
  62. Corbeil-Girard, 2005, PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions, Neurobiol. Dis., 18, 551, 10.1016/j.nbd.2004.10.019 · DOI
  63. Tavanez, 2009, Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1, PLoS One, 4, 10.1371/journal.pone.0006418 · DOI
  64. García-Castañeda, 2017, Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1, J. Physiol., 595, 4167, 10.1113/JP273948 · DOI
  65. Bahar, 2016, ER stress-mediated signaling: action potential and Ca(2+) as key players, Int. J. Mol. Sci., 17, 10.3390/ijms17091558 · DOI · Paper page
  66. Pinton, 2008, Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis, Oncogene, 27, 6407, 10.1038/onc.2008.308 · DOI · Paper page
  67. Lee, 2002, IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response, Genes Dev., 16, 452, 10.1101/gad.964702 · DOI · Paper page
  68. Morgan, 1994, Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines, Dev. Biol., 162, 486, 10.1006/dbio.1994.1103 · DOI · Paper page
  69. Holmes, 1983, Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension, Drugs, 26, 212, 10.2165/00003495-198326030-00003 · DOI
  70. Malerba, 2011, Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice, Mol. Ther., 19, 345, 10.1038/mt.2010.261 · DOI
  71. Yu, 2012, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS, 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page

Metadata

Authors
Malerba, A., Roth, F., Harish, P., Dhiab, J., Lu-Nguyen, N., Cappellari, O., Jarmin, S., Mahoudeau, A., Ythier, V., Lainé, J., Negroni, E., Abgueguen, E., Simonelig, M., Guedat, P., Mouly, V., Butler-Browne, G., Voisset, C., Dickson, G., & Trollet, C.
Affiliations
  • School of Biological Sciences, Centers of Gene and Cell Therapy and Biomedical Sciences, Royal Holloway, University of London, TW20 OEX Surrey, UK
  • Sorbonne Université, INSERM, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, 47 bd de l’Hôpital, Paris, France
  • Comparative Biomedical Sciences, The Royal Veterinary College, London, UK
  • Inflectis Bioscience, Nantes, France
  • Institute of Human Genetics, CNRS UMR9002-University of Montpellier, mRNA Regulation and Development, Montpellier, France
  • UMR1078 ‘Genetic, Functional Genomic and Biotechnologies’, INSERM, EFS, Brest University, IBSAM, Brest, France
Venue
Human Molecular Genetics
Published
2019-01-14
Volume
28
Issue
10
Pages
1694-1708
ISSN
  • 0964-6906
  • 1460-2083
Cited by
33
References
5
Language
en
Funders
  • Centre National de la Recherche Scientifique
  • Association Française contre les Myopathies (17110)
  • Sorbonne University association
  • Institut National de la Santé et de la Recherche Médicale

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.